Treatment trial for patients with non-small cell lung cancer and EGFR tumor mutation

Study ID: A081105

Randomized study of erlotinib vs. observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

This treatment study seeks to determine the efficacy of the oral medication erlotinib in patients who have been diagnosed with NSCLC and whose tumors show the presence of EGFR mutation. Some participants in this study will take erlotinib daily for two years.

Inclusion criteria:

  • Registered to A151216 for central tumor testing, if EGFT+ or EGFR & ALK rearrangement is present, coordinator will inform patient of eligibility
  • Completely recovered from surgery and post-op therapy; see protocol for details


  • Randomized to erlotinib (150mg/day) or observation
  • Patients randomized to erlotinib treatment will be treated for up to two years. Treatment will be discontinued at disease progression or excessive toxicity.

Additional schema information (PDF)

Inclusion Snapshot

Must have been diagnosed with NSCLC with EGFR mutation

Contact Information

Lankenau Institute for Medical Research trial